Publications by authors named "David Michelin"

Claim this Profile
L
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
Daniela E Matei, Danielle M Enserro, Marcus E Randall, David Mutch, William Small, David Michelin

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib in Patients With Solid Tumors With Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Vaibhav Sahai, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vijay Suhag, David P Michelin

JCO Precis Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma.
Joyce N Barlin, Barb Mahar, Ashar Ata, Beatrice Cormier, David Michelin

Gynecol Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
Joyce F Liu, Mark F Brady, Ursula A Matulonis, Austin Miller, Elise C Kohn, David P Michelin

J Clin Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming the Stress of Malpractice Litigation: Solutions to Help Physicians Stay Healthy and Engaged.
David P Michelin

Mich Med· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Lydia Usha, Michael W Sill, Kathleen M Darcy, Doris M Benbrook, Jean A Hurteau, David P Michelin

Gynecol Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
Maurie Markman, James Moon, Sharon Wilczynski, Ana Maria Lopez, Kendrith M Rowland, David P Michelin

Gynecol Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
David S Alberts, P Y Liu, Sharon P Wilczynski, Mary C Clouser, Ana Maria Lopez, David P Michelin

Gynecol Oncol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis